Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
Rituximab
Do you limit the duration of rituximab use in RA patients due to concerns about long term use such as permanent hypogammaglobulinemia?
Related Questions
Do you prefer to taper rituximab by extending the interval between doses or decreasing the actual dose administered for RA patients who have achieved longstanding remission?
For patients with RA and secondary loss of response to initial TNFi do you typically recommend an alternative TNFi or switch to a different mechanism of action?
Do you avoid the use of TNF inhibitors in patients with RA-ILD?
Do you consider Anti-carbamylated protein antibodies (anti-CarP) as having any significance in evaluation of patients if RF and ACPA negative and clinically no active synovitis yet widespread arthralgias and generalized osteoarthritis?
What is your approach to differentiating and managing DMARD-induced nodulosis (induced by methotrexate or leflunomide for example) from "de novo" RA nodules in seropositive RA patients?
Does the presence of bronchiectasis change your approach to a patient with otherwise well-controlled patient with RA?
Would you consider the use of doxycycline or minocycline in the management of RA?
Would you consider adding dupilumab to adalimumab (or other monoclonal antibodies) in a patient who has RA and refractory atopic dermatitis and already is on MTX 25 mg weekly?
Do you hold rituximab for cataract surgery?
How do you counsel patients who prefer to continue TNFi therapy indefinitely for rheumatoid arthritis despite long-standing remission?
